

**NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE**

**Single Technology Appraisal**

**Marstacimab for treating severe haemophilia A or moderately severe to severe haemophilia B in people 12 years and over ID6342**

**Provisional Stakeholder List**

<b>Consultees</b>	<b>Commentators (no right to submit or appeal)</b>
<p><u>Company</u></p> <ul style="list-style-type: none"> <li>• Pfizer (marstacimab)</li> </ul> <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> <li>• Black Health Agency for Equality</li> <li>• Gene People</li> <li>• Genetic Alliance UK</li> <li>• Haemophilia Society</li> <li>• Immunodeficiency UK</li> <li>• South Asian Health Foundation</li> <li>• Specialised Healthcare Alliance</li> </ul> <p><u>Healthcare professional groups</u></p> <ul style="list-style-type: none"> <li>• Association of Genetic Nurses &amp; Counsellors</li> <li>• British Blood Transfusion Society</li> <li>• British Committee for Standards in Haematology</li> <li>• British Geriatrics Society</li> <li>• British Paediatric Allergy, Immunity and Infection Group</li> <li>• British Society for Gene and Cell Therapy</li> <li>• British Society for Genetic Medicine</li> <li>• British Society for Haematology</li> <li>• British Society of Medical Genetics</li> <li>• Haemophilia Nurses Association</li> <li>• Royal College of General Practitioners</li> <li>• Royal College of Nursing</li> <li>• Royal College of Pathologists</li> <li>• Royal College of Physicians</li> <li>• Royal Pharmaceutical Society</li> <li>• Royal Society of Medicine</li> <li>• UK Clinical Pharmacy Association</li> <li>• UK Forum on Haemoglobin Disorders</li> </ul>	<p><u>General</u></p> <ul style="list-style-type: none"> <li>• All Wales Therapeutics and Toxicology Centre</li> <li>• Allied Health Professionals Federation</li> <li>• Board of Community Health Councils in Wales</li> <li>• British National Formulary</li> <li>• Care Quality Commission</li> <li>• Cell and Gene Therapy Catapult</li> <li>• Department of Health, Social Services and Public Safety for Northern Ireland</li> <li>• Haemophilia Scotland</li> <li>• Haemophilia Wales</li> <li>• Healthcare Improvement Scotland</li> <li>• Hospital Information Services - Jehovah's Witnesses</li> <li>• Medicines and Healthcare products Regulatory Agency</li> <li>• National Association of Primary Care</li> <li>• National Pharmacy Association</li> <li>• NHS Confederation</li> <li>• Scottish Medicines Consortium</li> <li>• Welsh Government</li> <li>• Welsh Health Specialised Services Committee</li> </ul> <p><u>Possible comparator companies</u></p> <ul style="list-style-type: none"> <li>• Bio Products Laboratory (factor IX, factor VIII)</li> <li>• CSL Behring (etranacogene dezaparvovec, factor IX, factor VIII)</li> <li>• Grifols UK (factor IX, factor VIII)</li> <li>• Novo Nordisk Ltd (factor VIII, eptacog alpha, nonacog beta pegol turoctocog alfa pegol)</li> </ul>

Provisional stakeholder list for the evaluation of marstacimab for treating severe haemophilia A or moderately severe to severe haemophilia B in people 12 years and over ID6342

Issue date: January 2024

Consultees	Commentators (no right to submit or appeal)
<ul style="list-style-type: none"> <li>• UK Haemophilia Centre Doctors' Organisation</li> </ul> <p><u>Others</u></p> <ul style="list-style-type: none"> <li>• Department of Health and Social Care</li> <li>• NHS England</li> </ul>	<ul style="list-style-type: none"> <li>• Octapharma (factor VIII, simoctocog alfa)</li> <li>• Pfizer (fidanacogene elaparvovec, moroctocog alfa, nonacog alfa)</li> <li>• Roche (emicizumab)</li> <li>• Swedish Orphan Biovitrum (efmoroctocog alfa, eftrenonacog alfa)</li> <li>• Takeda (factor IX, octocog alfa, ruriocog alfa pegol, susocog alfa)</li> </ul> <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> <li>• Cochrane Cystic Fibrosis &amp; Genetic Disorders Group</li> <li>• Cochrane Haematology</li> <li>• Cochrane UK</li> <li>• Genomics England</li> <li>• Haemnet</li> <li>• MRC Clinical Trials Unit</li> <li>• National Institute for Health Research</li> <li>• NHS Oxford Haemophilia and Thrombosis Centre</li> <li>• NHS Southern Haemophilia Network</li> </ul> <p><u>Associated Public Health groups</u></p> <ul style="list-style-type: none"> <li>• Public Health Wales</li> <li>• UK Health Security Agency</li> </ul>

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

**Definitions:**

Consultees

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).

All non-company consultees are invited to submit a statement relevant to the group they are representing, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).

### Commentators

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC]); other groups (for example, the NHS Confederation and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.